Amneal Pharmaceuticals, Inc. (AMRX)
NASDAQ: AMRX · Real-Time Price · USD
17.44
0.00 (0.00%)
Sep 4, 2026, 4:00 PM EDT - Market closed

Amneal Pharmaceuticals Balance Sheet

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
127.64282.03110.5591.5425.98247.79
Short-Term Investments
3.784.441.872.21.821.17
Cash & Short-Term Investments
131.41286.47112.4293.7427.8248.96
Cash Growth
74.56%154.82%19.93%237.24%-88.83%-27.43%
Accounts Receivable
1,020895.14775.73613.73741.79662.58
Other Receivables
62.2744.7332.8331.9354.6232.06
Receivables
1,083939.87808.56645.66796.41694.64
Inventory
677.95606.3612.45581.38530.74489.39
Prepaid Expenses
46.3949.746.549.5147.1345.07
Restricted Cash
8.6428.847.877.579.258.95
Other Current Assets
----0.533.1
Total Current Assets
1,9471,9111,5881,3781,4121,520
Property, Plant & Equipment
567.32550.33523.69550.14589.36639
Long-Term Investments
16.215.7635.9237.0985.59-
Goodwill
593.5595.47597.44598.63598.85593.02
Other Intangible Assets
587.83563.5732.38890.421,0961,167
Long-Term Deferred Charges
4.625.22.824.432.211.6
Other Long-Term Assets
59.8446.8521.391415.4319.01
Total Assets
3,7763,6783,5013,4733,7993,940

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Accounts Payable
244.48254.93259.84145.53166.84132.87
Accrued Expenses
290.03328.59317.53246.01218.21220.57
Short-Term Debt
100-10017960-
Current Portion of Long-Term Debt
5.966.76224.2134.1329.9630.61
Current Portion of Leases
15.4614.8216.0414.514.6815.42
Current Income Taxes Payable
-----2.52
Other Current Liabilities
227.25276.54212.14227.43263.11275.24
Total Current Liabilities
883.19881.631,130846.6752.8677.24
Long-Term Debt
2,5642,5652,1622,4272,6322,730
Long-Term Leases
106.01102.3691.0995.45108.81111.93
Other Long-Term Liabilities
105.84123.21163.3341.7797.1237.05
Total Liabilities
3,6593,6723,5463,4113,5903,556

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Common Stock
3.193.153.13.073.043.01
Additional Paid-In Capital
545.58571.79560.21539.24691.63658.35
Retained Earnings
-415.09-535.01-607.06-490.18-406.18-276.2
Comprehensive Income & Other
-100.67-110.73-65.51-32.359.94-24.83
Total Common Equity
33.02-70.79-109.2719.78298.42360.34
Minority Interest
83.9676.7664.7341.52-89.4923.54
Shareholders' Equity
116.985.96-44.5461.3208.93383.88
Total Liabilities & Equity
3,7763,6783,5013,4733,7993,940

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Total Debt
2,7922,6892,5932,7512,8452,888
Net Cash (Debt)
-2,660-2,403-2,481-2,657-2,817-2,639
Net Cash Growth
------
Net Cash Per Share
-8.12-7.40-8.03-15.08-18.66-17.38
Filing Date Shares Outstanding
319.35314.63309.97307.01151.5149.42
Total Common Shares Outstanding
319.33314.57309.88306.57151.49149.41
Working Capital
1,0641,030458.04531.27659.02842.87
Book Value Per Share
0.10-0.23-0.350.061.972.41
Tangible Book Value
-1,148-1,230-1,439-1,469-1,397-1,400
Tangible Book Value Per Share
-3.60-3.91-4.64-4.79-9.22-9.37
Land
-19.698.119.0210.7111.54
Buildings
-234.6224.66227.84225.63230.99
Machinery
-568.09546.56524.61485.44484.42
Construction In Progress
-92.9178.267.6769.3458.26
Leasehold Improvements
-133.83130.91126.46124.67123.51
SEC Filings: 10-K · 10-Q